Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus
Open Access
- 22 June 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 60 (2) , 406-409
- https://doi.org/10.1093/jac/dkm211
Abstract
This study compared the activity of telavancin, a novel multivalent lipoglycopeptide with rapid bactericidal activity, with those of five standard antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) against isolates of community-associated MRSA (CA-MRSA). Microdilution tests performed according to CLSI guidelines using cation-adjusted Mueller–Hinton broth were used to determine the MIC values of telavancin, quinupristin/dalfopristin, vancomycin, trimethoprim/sulfamethoxazole, linezolid and daptomycin versus 60 CA-MRSA isolates. MBC values of telavancin were determined according to CLSI guidelines and American Society for Microbiology standards. PFGE was performed using the restriction enzyme SmaI. Samples from three predominant pulsed-field types were typed by multilocus sequence typing. Staphylococcal cassette chromosome mec typing was determined by multiplex PCR. The Panton-Valentine leucocidin (PVL) genes (lukS-PV and lukF-PV) were identified by PCR. The telavancin MIC90 and MBC90 values for this collection of 60 CA-MRSA isolates were 0.5 and 1 mg/L, respectively, with MIC and MBC values both ranging from 0.25 to 1 mg/L. Telavancin was found to be bactericidal in this study, as its MBC was no more than 2-fold higher than its MIC for all CA-MRSA isolates tested except one. (A single isolate yielded an MBC/MIC ratio of 4.) PVL- and non-PVL-producing strains demonstrated similar susceptibility to telavancin and comparator agents. Based on in vitro activity, telavancin should be an effective agent against CA-MRSA.Keywords
This publication has 8 references indexed in Scilit:
- Emergence of Community-Associated Methicillin-ResistantStaphylococcus aureusInfection Among Patients With End-Stage Renal DiseaseInfection Control & Hospital Epidemiology, 2006
- Methicillin-ResistantS. aureusInfections among Patients in the Emergency DepartmentNew England Journal of Medicine, 2006
- Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureusJournal of Antimicrobial Chemotherapy, 2006
- Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 StudyAntimicrobial Agents and Chemotherapy, 2006
- Clinical and Laboratory Features of Community-Associated Methicillin-ResistantStaphylococcus aureus:Is It Really New?Infection Control & Hospital Epidemiology, 2006
- Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2005
- Pharmacokinetics, Serum Inhibitory and Bactericidal Activity, and Safety of Telavancin in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2005
- Methicillin-Resistant Staphylococcus aureusAnnals of Internal Medicine, 1982